Full history for every metric is available with a Kvantra account
Living Cell Technologies Limited (LCT.AX)
Key financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | AUD m | -2 | -2 | |||||
| Net profit | AUD m | -3 | -1 | -1 | -2 | -2 | -2 | -2 |
| EPS reported | AUD | -0.00 | -0.00 | |||||
| Operating cashflow per share | AUD | -0.00 | -0.00 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.00 | -0.00 | |||||
| Free cash flow | AUD m | -2 | -2 | |||||
| Net debt | AUD m | -3 | -3 | |||||
| Book value equity | AUD m | 3 | 3 | |||||
| Book value per share | AUD | 0.00 | 0.00 | |||||
| Number of shares | m | 1,663.11 | 1,686.44 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.56 | 8.14 | |||||
| P/S LTM | x | 206.16 | 195.96 | |||||
| P/FCF LTM | x | -16.94 | -16.11 | |||||
| EV/EBITDA LTM | x | -14.38 | -21.32 | |||||
| EV/Sales LTM | x | 181.33 | 171.14 | |||||
| Earnings Yield LTM | % | -8.12% | -8.66% | |||||
| FCF Yield | % | -5.90% | -6.21% | |||||
| Quality | ||||||||
| ROE | % | -69.52% | -61.85% | |||||
| ROIC | % | -68.93% | -68.93% | |||||
| Operating margin | % | -1659.5% | -1659.5% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -1216.7% | -1216.7% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +197.98% | +197.98% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.97 | 1.97 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -12.04% | -12.67% | |||||
| Net debt/Equity | x | -1.03 | -1.03 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Established in Sydney, Australia, in 1987, Living Cell Technologies Limited is a biotechnology firm focused on identifying, advancing, and bringing to market regenerative therapies. These innovative treatments leverage natural cellular processes to re-establish biological functions for patients, primarily across Australia and New Zealand. A key undertaking for the company is NTCELL, an alginate-encapsulated product currently in phase IIb clinical trials as a potential therapy for Parkinson's disease.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Living Cell Technologies Limited (LCT.AX)
Established in Sydney, Australia, in 1987, Living Cell Technologies Limited is a biotechnology firm focused on identifying, advancing, and bringing to market regenerative therapies. These innovative treatments leverage natural cellular processes to re-establish biological functions for patients, primarily across Australia and New Zealand. A key undertaking for the company is NTCELL, an alginate-encapsulated product currently in phase IIb clinical trials as a potential therapy for Parkinson's disease.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free